CD30 on extracellular vesicles from malignant Hodgkin cells supports damaging of CD30 ligand-expressing bystander cells with Brentuximab-Vedotin, in vitro.
Hansen HP, Trad A, Dams M, Zigrino P, Moss M, Tator M, Schön G, Grenzi PC, Bachurski D, Aquino B, Dürkop H, Reiners KS, von Bergwelt-Baildon M, Hallek M, Grötzinger J, Engert A, Paes Leme AF, Pogge von Strandmann E.
Hansen HP, et al. Among authors: von bergwelt baildon m, pogge von strandmann e.
Oncotarget. 2016 May 24;7(21):30523-35. doi: 10.18632/oncotarget.8864.
Oncotarget. 2016.
PMID: 27105521
Free PMC article.